CompanyDrug

Dizal Pharmaceutical’s Golidocitinib NDA Accepted for Review by NMPA

CompanyMedical Device

Genesis MedTech Receives Chinese Market Approval for Antibacterial Absorbable Sutures

CompanyDrug

Grand Pharmaceutical’s GSP301 NS Meets Primary Endpoint in Phase III SAR Study

CompanyDeals

Canton Biologics Secures Over RMB 300 Million in Series C Financing for Expansion

CompanyDeals

Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan

CompanyDrug

Haisco Pharmaceutical’s HSK16149 for Post-Herpes Neuralgia Accepted for NMPA Review

CompanyDrug

Asieris Pharmaceuticals’ APL-1202 Shows Positive Interim Analysis in MIBC Trial with BeiGene’s Tislelizumab

CompanyDrug

AstraZeneca’s Fasenra Shows Non-Inferior Efficacy to Nucala in EGPA: Phase III Results

CompanyDrug

InnoCare Pharma and ArriVent Biopharma Partner on Clinical Study for Advanced NSCLC Treatment

CompanyDrug

EMA Approves Astellas’ Xtandi for Non-Metastatic Hormone-Sensitive Prostate Cancer

CompanyDrug

FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease

CompanyDrug

AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial